News Release

PM2.5 exposure may affect lung cancer in women who have never smoked

Reports and Proceedings

International Association for the Study of Lung Cancer

Dr. Yixian Chen, a researcher at British Columbia Cancer Research Institute, Vancouver, Canada.

image: 

Dr. Yixian Chen, a researcher at British Columbia Cancer Research Institute, Vancouver, Canada.

view more 

Credit: Dr. Yixian Chen, a researcher at British Columbia Cancer Research Institute, Vancouver, Canada.

(San Diego, Calif.--September 10, 2024, 10:35 a.m. PCT) – Recent air pollution exposure in the form of particles smaller than 2.5 micrometers (PM2.5) exposure may significantly impact lung cancer in women who have never smoked, with notable differences in stage IV diagnoses among EGFR+ patients, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer.

The International Agency for Research on Cancer (IARC) categorized outdoor air pollution and its key component, particulate matter PM2.5, as Group 1 carcinogens in 2013, indicating that they cause lung cancer. Associations between tobacco use and lung cancer account for a majority of lung cancers. Still, researchers and public health experts have not been able to identify an association that explains why individuals who do not smoke or have never smoked are diagnosed with lung cancer.

“The timing and duration of PM2.5 exposure that are most relevant for the development of lung cancer and lung cancer risk have not been well characterized. The purpose of our study is to compare the associations between recent versus long-term cumulative PM2.5 exposure in men and women who had never smoked and lung cancer EGFR mutation status,” said Dr. Yixian Chen, a researcher at British Columbia Cancer Research Institute, Vancouver, Canada.

The research team collected data from newly diagnosed lung cancer patients who never smoked that included information on their residential history from birth to the date of diagnosis. Dr. Chen and the team then geocoded each residential address and analyzed high-resolution concentration estimates of PM2.5 exposure from satellite data, chemical transport models, and ground measurements within roughly 10 x 10 kilometer areas corresponding to the time the individual lived at each address. The team obtained annual exposure data going back to 1996 when accurate air pollution information became available globally.

A total of 255 patients with known EGFR mutation status were included in the analysis. Significant associations were observed between EGFR mutation and cancer stage among women (p=0.197 in men, p<0.001 in women). Patients diagnosed with stage IV lung cancer displayed higher proportions of EGFR mutations compared to those without. Notable differences were also identified in the cumulative 3-year PM2.5 exposure before diagnosis in women who never smoked with EGFR mutations compared to those without (e.g., 19.0 vs 17.3 μg/m3, p=0.031). This trend persisted when examining cumulative 5-year exposure (33.7 vs 29.5 μg/m3, p=0.024) before diagnosis, with higher exposure observed in the EGFR-mutation positive group (EGFR+). Surprisingly, these associations were not evident in men who never smoked. Moreover, long-term exposure, such as 10-, 15-, and 20-year cumulative exposure to PM2.5, was not associated with EGFR mutation status in either men or women.

These findings suggest a potential impact of recent exposure to PM2.5 on lung cancer in people who never smoked, particularly among women, with significant differences in stage IV diagnoses among EGFR+ patients,” said Dr. Chen. “Further studies are needed to confirm if PM2.5 measurement over 3 to 5 years is adequate for lung cancer risk assessment.”

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:

The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2024.iaslc.org.

 

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.